ClinicalTrials.gov
public full text
Public Domain
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who are in syndromic and symptomatic remission at the time of enrollment into the study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation#991968
- Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study#181829
- Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion#877234
- A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia#883912
- Dealing With Intrusive Thoughts in OCD - a Comparison of Detached Mindfulness and Cognitive Restructuring#1087896
Record · ID 876966
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive